For the Quarter Ending March 2026
Valsartan Prices in APAC
- In China, the Valsartan Price Index fell by 3.16% quarter-over-quarter, reflecting steady supply and softer export demand.
- The average Valsartan price for the quarter was approximately USD 51626.67/MT. reported by FOB Zhenjiang data sources.
- Valsartan Spot Price firmed in March as Zhejiang maintenance trimmed exportable lots, lifting short-term seller confidence margins.
- Valsartan Price Forecast shows modest increases into April, driven by repaired demand and temporary supply reductions persisting.
- Valsartan Production Cost Trend remained elevated due to higher solvent recovery and electricity tariffs affecting Jiangsu processors.
- Valsartan Demand Outlook strengthened as international formulators accelerated procurement ahead of upcoming cardiovascular patent expiries, increasing bookings.
- Valsartan Price Index volatility reflected alternating inventory builds and sudden feedstock shortages restricting short-term shipments and exports.
- Exporters offered flexible commercial terms to clear comfortable inventories while maintaining disciplined FOB offers and shipment schedules.
Why did the price of Valsartan change in March 2026 in APAC?
- Scheduled Zhejiang maintenance removed spot capacity, tightening exportable volumes and prompting stronger seller pricing discipline in March.
- Intermittent feedstock constraints and higher electricity-driven solvent recovery costs elevated marginal production costs in Marc,h pushing offers.
- Buyers accelerated procurement ahead of patent expiries while exporters reduced spot availability, combining to lift FOB values.
Valsartan Prices in Europe
- In Germany, the Valsartan Price Index fell by 3.13% quarter-over-quarter, reflecting reduced exporter availability pressures.
- The average Valsartan price for the quarter was approximately USD 51726.67/MT based on CFR Hamburg.
- March supply reduction temporarily lifted the Valsartan Spot Price as Indian export declarations declined sharply.
- Short-term Valsartan Price Forecast anticipates modest easing as buying remains cautious despite tight prompt availability.
- Higher energy and feedstock costs influenced the Valsartan Production Cost Trend, remaining secondary to supply.
- German Valsartan Demand Outlook remains steady with tender-driven buying and hospital replenishment ahead of auctions.
- Valsartan Price Index showed inventory draws and shipment delays, prompting suppliers to offer flexible terms.
- Exporters maintained steady output while audits and domestic tendering in India reduced spot cargo availability.
Why did the price of Valsartan change in March 2026 in Europe?
- Indian production pullback and audit-driven plant adjustments reduced export volumes, tightening prompt German import availability.
- Chinese extended Lunar New Year maintenance delayed shipments, shortening seaboard inventories and accelerating replenishment purchases.
- Domestic tender cycles induced wholesalers to top up safety stocks, increasing demand and supporting offers.
Valsartan Prices in North America
- In the USA, the Valsartan Price Index fell by 3.14% quarter-over-quarter, reflecting tightened spot availability and testing delays.
- The average Valsartan price for the quarter was approximately USD 51750.00/MT, reported by importers and distributors.
- Recent Valsartan Spot Price strength reflected port-testing delays and reallocations of merchant cargoes to alternate markets.
- Near-term Valsartan Price Forecast remains modestly bullish as emergency restocking and litigation-driven precautionary buying support offers.
- Valsartan Production Cost Trend stable due to muted energy and solvent costs, limiting pass-through for origin sellers.
- Valsartan Demand Outlook steady across retail and hospital channels, encouraging measured procurement rather than aggressive stock accumulation.
- Elevated Valsartan Price Index volatility in March prompted buyers to prioritize secured cargoes over speculative tendering strategies.
- Inventories tightened as FDA testing delayed clearance in March, reducing export flexibility and supporting prompt-market premiums.
Why did the price of Valsartan change in March 2026 in North America?
- Extended FDA nitrosamine testing delayed customs clearance, temporarily tightening prompt availability and elevating immediate purchase urgency.
- Distributors rebuilt precautionary inventories following litigation settlements, reducing market buffers and increasing near-term purchase activity.
- Steady Asian production and muted procurement, combined with aggressive GPO tendering, constrained sustained price recovery momentum.
For the Quarter Ending December 2025
North America
• In the USA, the Valsartan Price Index fell by 4.52% quarter-over-quarter, reflecting abundant imports and inventory.
• The average Valsartan price for the quarter was approximately USD 75950.00/MT, reflecting competitive import offers.
• Valsartan Spot Price softened as steady shipments from India and China limited seller pricing power.
• Valsartan Price Forecast suggests modest downside near-term as exporters clear inventories and buyers delay tenders.
• Valsartan Production Cost Trend improved slightly from lower precursor costs and stable energy at origins.
• Valsartan Demand Outlook remains steady with routine antihypertensive consumption, while buyers tactically postpone large purchases.
• Policy-driven purchasing and GPO tendering pressured the Valsartan Price Index, constraining sellers' pricing power further.
• Normalized freight and stable port operations underpinned supply comfort, preventing meaningful spot tightness recovery.
Why did the price of Valsartan change in December 2025 in North America?
• Sustained import volumes from India and China increased availability, reducing buyer urgency and price pressure.
• Lower precursor costs and stable origin energy reduced production costs, transmitting softer landed parity margins.
• Year-end inventory reductions and cautious GPO tendering softened demand, limiting upward pricing pressure during December.
APAC
• In China, the Valsartan Price Index fell by 4.5% quarter-over-quarter, pressured by softer export demand and inventory builds.
• The average Valsartan price for the quarter was approximately USD 75830.00/MT, reflecting FOB Zhenjiang offers and export competitiveness.
• Valsartan Spot Price remained subdued as the Price Index reflected mild discounting amid steady manufacturing output and inventories.
• Valsartan Price Forecast indicates modest recovery potential as buyers resume planned procurement for early 2026, cautiously optimistic.
• Valsartan Production Cost Trend remained stable with flat feedstock and energy costs, limiting any immediate upward pressure.
• Valsartan Demand Outlook stays balanced, dominated by routine hypertension procurement, restrained by pre-built inventories offshore.
• Valsartan Price Index volatility eased as exporters accepted marginal discounts to clear three-week warehouse inventory backlogs.
• Major Zhejiang and Jiangsu plants ran near nameplate capacity, supporting steady exports and manageable vessel turnaround schedules.
Why did the price of Valsartan change in December 2025 in APAC?
• Post-Golden Week production resumptions increased availability, easing previous supply constraints and pressuring export-oriented offers in December.
• Stable feedstock and energy costs prevented cost-push inflation, keeping producers' variable costs unchanged through the month.
• Seasonally subdued European and US buying reduced spot inquiries, while exporters cleared inventories through marginal discounts.
Europe
• In Germany, the Valsartan Price Index fell by 4.53% quarter-over-quarter in Q4 2025, from imports.
• The average Valsartan price for the quarter was approximately USD 75906.67/MT, reflecting CFR supplier offers.
• Valsartan Spot Price remained pressured as buyers delayed purchases pending tender outcomes, sustaining downward momentum.
• Valsartan Price Forecast signals modest downside risk near-term as ample imports and tender-driven competition persist.
• Valsartan Production Cost Trend eased as tetrazole intermediate prices softened across Asia, reducing synthesis overheads.
• Valsartan Demand Outlook remains stable with chronic hypertension prescriptions, while procurement discipline limits spot buying.
• Valsartan Price Index displays mild bearish bias as distributors reduce buffer inventories before tender awards.
• Inventory levels remained comfortable while Hamburg port efficiency supported steady CFR arrivals, limiting logistics-driven premia.
Why did the price of Valsartan change in December 2025 in Europe?
• Abundant CFR imports from India and China increased supply, pressuring buyer-negotiated landed prices in December.
• Tender-driven purchasing discipline and Festbetrag reimbursement caps constrained distributor willingness to accept higher invoice levels.
• Softer tetrazole intermediate costs in Asia reduced FOB quotes, while freight and currency stayed neutral.
For the Quarter Ending September 2025
North America
• In USA, the Valsartan Price Index fell by 2.44% quarter-over-quarter in Q3 2025, reflecting destocking pressures.
• The average Valsartan price for the quarter was approximately USD 79546.67/MT reflecting subdued transactional activity and strategic inventory drawdown.
• Valsartan Spot Price softened as import slowdowns and improved logistics reduced freight premiums and selling leverage.
• Valsartan Price Forecast indicates mild near-term softness with potential modest recovery into late Q4 as inventories normalize.
• Valsartan Production Cost Trend showed easing logistics and stable feedstock inputs, marginally relieving upward cost pressure on producers.
• Valsartan Demand Outlook remains weak as buyers delay purchases amid tariff uncertainty and cautious healthcare procurement policies.
• Valsartan Price Index stability hampered by distributor undercutting and spot deals aimed at clearing accumulated inventories quickly.
• Operational restarts and staggered importer restocking may modestly lift demand, but balanced stocks constrain significant price rebounds.
Why did the price of Valsartan change in September 2025 in North America?
• Excess inventories from earlier stockpiling reduced buying urgency, weakening spot demand and pressure on prices.
• Improved logistics and falling freight costs lowered landed costs, enabling sellers to discount, stimulate sales.
• Tariff uncertainty prompted cautious procurement, delaying orders and suppressing immediate demand across pharmaceutical distributors domestically.
APAC
• In China, the Valsartan Price Index fell by 2.397% quarter-over-quarter, driven by export demand weakness.
• The average Valsartan price for the quarter was approximately USD 79400.00/MT, reflecting sustained exporter discounts and inventory clearance.
• Valsartan Price Index shows steady downward pressure as exporters aggressively discount to clear inventories globally.
• Valsartan Spot Price activity remained subdued amid logistics delays and reduced international procurement volumes overall.
• Valsartan Production Cost Trend eased as freight rates declined and input PPI weakness reduced marginal manufacturing expenses.
• Valsartan Demand Outlook remains weak with buyers delaying purchases, favoring inventory drawdown over fresh contracts.
• Valsartan Price Forecast anticipates modest further softening before potential year-end buying partially stabilizes traded levels.
• Valsartan Price Index impacted by port disruptions, holiday season effects, and intensified export competition among Chinese producers.
Why did the price of Valsartan change in September 2025 in APAC?
• Export demand remained muted as buyers consumed inventories and delayed fresh procurement, reducing immediate order volumes.
• Lower freight costs and removal of surcharges eased cost pressures, giving buyers stronger negotiating leverage.
• Stable production alongside rising inventories and occasional logistics delays pressured sellers to cut prices to stimulate offtake.
Europe
• In Germany, the Valsartan Price Index fell by 2.41% quarter-over-quarter, reflecting elevated inventory and subdued activity.
• The average Valsartan price for the quarter was approximately USD 79511.67/MT, supporting cautious buyer patterns.
• Valsartan Spot Price lagged behind contracts as the Valsartan Price Index reflected oversupply and muted buying interest.
• Valsartan Price Forecast indicates modest declines before stabilizing, driven by inventory digestion and buying patterns.
• Valsartan Production Cost Trend remained subdued as freight deferrals and feedstock costs limited upward price pressure.
• Valsartan Demand Outlook stays weak near-term due to adequate stocks and cautious procurement by buyers.
• Export availability from Asia pressured prices, while distributors cleared stock, keeping the Valsartan Price Index soft.
• Maintenance-driven exports and geopolitical shipping risks intermittently influenced availability, moderating any immediate Valsartan price rebounds.
Why did the price of Valsartan change in September 2025 in Europe?
• High inventories and cautious procurement depressed spot activity, reducing urgency and downward pressure on prices.
• Port congestion and deferred PSS limited immediate freight cost escalation, preventing short-term price increases significantly.
• Increased export offers from Chinese suppliers and subdued downstream demand intensified competitive pricing pressure further.
For the Quarter Ending June 2025
North America
• The Valsartan Price Index in the USA showed mixed trends in Q2 2025: declining by 0.99% in April, rising sharply by 3.15% in May, then falling again by 1.05% in June.
• In April, the Product Spot Price softened due to high tariffs (145%) on Chinese imports, strategic frontloading of shipments, and inventory buildup leading to reduced new orders and price cuts to clear stock.
• The Product Production Cost Trend was affected by tariffs, but partial absorption of these costs by supply chain players helped limit price increases in April.
• May saw a significant surge in the Price Index driven by a 90-day tariff suspension on Chinese pharma imports, prompting large-scale procurement and freight capacity strain that increased landed costs.
• The freight logistics bottlenecks, including port congestion and equipment shortages, contributed to higher Valsartan Spot Prices and elevated Product Production Cost Trend in May.
• Demand surged in May as distributors and buyers front-loaded orders ahead of anticipated tariff reinstatements, supported by modest U.S. inflation (0.1%) and expectations of General Rate Increases (GRI).
• June reversed the trend with a declining Price Index, as buyers slowed purchasing due to tariff uncertainty, existing stockpiles, and easing ocean freight rates.
• The Product Demand Outlook weakened in June amid fragile U.S. business and consumer confidence, with usual seasonal demand upticks failing to appear early.
• Mid-year inventory normalization and destocking efforts by pharmaceutical distributors exerted downward pressure on prices during June.
• Price Forecast for July 2025 indicates continued price softness, as demand remains weak with buyers maintaining a cautious “wait and watch” stance, and excess inventory from June further widening the supply-demand gap.
APAC
• The Valsartan Price Index in China fell by 0.99% in April due to weak international demand and ongoing inventory pressure amid disrupted manufacturing and port congestion.
• China’s manufacturing sector contracted sharply in April with the PMI dropping to 49.0, reflecting a deep slowdown that pressured Valsartan production and export logistics.
• U.S. tariffs at 145% heavily dampened export demand, leading to cancellations and half-filled shipments; this forced sellers to offer steep discounts to clear high Valsartan stockpiles.
• Domestic consumption remained sluggish throughout April, compounding the weak Valsartan Demand Outlook and resulting in bearish market sentiment.
• In May, the Valsartan Price Index rebounded sharply by 3.13%, driven by surging international demand as U.S. buyers frontloaded orders ahead of the tariff reprieve expiry.
• Freight capacity tightened and shipping rates rose by 27%, accelerating distribution and firming up prices due to intense competition for container space.
• Exporters saw improved inventory turnover and boosted pricing power amid strong market momentum and narrowing supply.
• June saw a 1.15% decline in the Valsartan Price Index, pressured by overcapacity, falling freight costs, and subdued global demand as buyers delayed purchases expecting lower prices.
• China's Producer Price Index fell 3.6% YoY in June, signaling weak input costs and limited pricing power for Valsartan producers.
• Valsartan Spot Price in July is expected to remain under downward pressure as excess inventories persist and international buyers continue a cautious, “wait and watch” approach despite stable production levels.
Europe
• The Price Index for Valsartan in Germany declined by 0.99% in April, driven by oversupply caused by US tariffs rerouting shipments to Europe and pre-holiday stocking by buyers.
• April’s supply glut, combined with subdued demand, resulted in abundant inventories, pressuring the Product Spot Price downward.
• Logistics disruptions such as port congestion and labor shortages in April constrained demand further, prompting cautious procurement from pharmaceutical buyers.
• In May, the Price Index reversed course, rising sharply by 3.12% due to escalating congestion at Northern European ports and limited vessel capacity, tightening supply availability.
• Anticipation of June’s General Rate Increase (GRI) fueled increased procurement activity and boosted the Product Demand Outlook, encouraging buyers to secure cargo early.
• Shipping reconfigurations shifted capacity back to Trans-Pacific routes, easing European oversupply and supporting upward price momentum in May.
• June saw the Price Index ease by 0.99% amid elevated inventory levels and a more conservative procurement stance, with buyers focused on liquidating stock before mid-year.
• Persistent logistical bottlenecks in June did not translate into immediate freight cost hikes, as carriers postponed Peak Season Surcharges (PSS), contributing to softer pricing.
• The Product Production Cost Trend remained stable, with no significant input cost spikes noted despite ongoing port congestion.
• For July 2025, the Product Price Forecast indicates likely price declines as excess inventory from June continues, demand remains weak, and buyers maintain a wait-and-watch approach, reinforcing the existing supply-demand imbalance.
